Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Formononetin Protects Neurons During Oxaliplatin Therapy
2026-08-13
The reference study identifies formononetin as a neuroprotective isoflavone that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway. Its most important translational finding is that neuronal protection was retained without weakening oxaliplatin or paclitaxel anticancer activity in the tested cancer-cell models, although protection against paclitaxel-related neurite damage was limited.
Clozapine: A Translational Assay Framework
2026-08-12
Clozapine is an atypical antipsychotic medication with a distinctive receptor and ERK1/2 signaling profile. This article develops a practical, cross-scale assay framework linking pharmacology, prefrontal circuitry, magnetic neuromodulation, and hepatotoxicity studies.
Adefovir: From HBV Polymerase to Renal Risk
2026-08-12
Adefovir and GS-0393 connect HBV polymerase inhibition with OAT1-mediated renal handling. This evidence-led guide translates mechanism, exposure, and adefovir-associated phosphate wasting into more discriminating research assay decisions.
FGFR1 as a Druggable Target in Schizophrenia
2026-08-11
A 2025 Molecular Neurobiology study integrated genetic causal-inference methods, colocalization, phenome-wide screening, drug prediction, docking, and single-cell analysis to identify six druggable genes associated with schizophrenia. FGFR1 emerged as the leading candidate, but the findings remain target-discovery evidence rather than proof of clinical efficacy or a validated schizophrenia treatment.
Deep Learning Maps Cardiotoxicity in iPSC-CMs
2026-08-11
Grafton et al. developed a scalable phenotypic screen that combines high-content imaging of induced pluripotent stem cell-derived cardiomyocytes with deep learning to identify cardiotoxic patterns. The approach detected liabilities across mechanistically diverse compounds and provides a practical framework for earlier toxicity triage during discovery and lead optimization.
Thiothixene: Efferocytosis Workflow and Research Outlook
2026-08-10
Thiothixene combines established dopamine and serotonin receptor pharmacology with a practical research use-case in macrophage efferocytosis assays. This guide translates that dual profile into an executable cell workflow, controls, troubleshooting logic, and a cautious bridge to emerging schizophrenia target-discovery research.
Homoharringtonine and SARS-CoV-2: Study Analysis
2026-08-09
The reference study evaluates Homoharringtonine as a broad coronavirus replication inhibitor and combines in vitro, mouse, and early human evidence. Its central innovation is a proposed upper-respiratory-tract intervention based on protein-elongation inhibition, although the small, uncontrolled clinical cohorts require cautious interpretation and further validation.
Uridine, Trisodium Salt for RNA Workflows
2026-08-08
Uridine, Trisodium Salt supports cell-based RNA metabolism studies and vascular assays while helping researchers control reagent solubility and nucleotide handling. Its most useful role in PRINT workflows is as a carefully characterized cellular input and assay variable—not as a direct substitute for UTP in in vitro transcription.
Cucurbitacin I: A Causal Perturbation Playbook
2026-08-07
Cucurbitacin I (JSI-124) is more than a STAT3 pathway inhibitor: it is a useful causal probe when molecular, phenotypic, and multicellular assay layers are aligned. This article connects its oncology applications with design principles from human SAN-plexus assembloids while clearly separating methodological insight from unsupported cardiac claims.
Brassinolide: Precision Tool for Plant Growth and Apoptosis
2026-08-07
Brassinolide (24-Epibrassinolide) stands out as a dual-function molecule, enabling high-performance plant growth modulation and targeted apoptosis studies in oncology and metabolic disease models. This guide delivers expert protocol enhancements, troubleshooting strategies, and actionable insights for maximizing assay reliability with APExBIO’s Brassinolide.
Zolmitriptan: 5-HT1B Receptor Agonist in Migraine Research M
2026-08-06
Zolmitriptan empowers migraine and cluster headache research by targeting 5-HT1B, 5-HT1D, and 5-HT1F receptors with high purity and reproducibility. This article delivers actionable protocols, advanced applications, and troubleshooting strategies to optimize serotonin receptor pharmacology workflows.
Palonosetron Hydrochloride: Beyond Antiemesis—Mechanistic Pr
2026-08-06
Discover how Palonosetron hydrochloride, a highly selective 5-HT3 receptor antagonist, redefines assay precision and translational research in oncology and transporter studies. This article explores mechanistic insights and advanced applications that go beyond current clinical paradigms.
CDC42-YAP-mTOR Axis Governs Intestinal Stem Cell Fate Transi
2026-08-05
This study establishes that CDC42-driven apical-basal polarity in intestinal stem cells orchestrates the crucial balance between stem cell maintenance and transit amplifying cell expansion through a Hippo-YAP-EGF-mTOR signaling cascade. These mechanistic insights refine our understanding of epithelial renewal and offer new targets for gastrointestinal homeostasis research.
Docosahexaenoic Acid (DHA): Applied Workflows for Neuroprote
2026-08-05
Docosahexaenoic Acid (DHA) is reshaping neuroprotection workflows by restoring lipid homeostasis and reducing postoperative cognitive dysfunction through targeted intervention. This article delivers actionable protocols, troubleshooting strategies, and highlights from spatial metabolomics, empowering researchers to leverage DHA’s unique properties in advanced bench setups.
Mc-Val-Cit-PABC-PNP: Protocol Guidance for ADC Peptide Linke
2026-08-04
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable ADC peptide linker intended for organic solvent-based antibody-drug conjugate synthesis, enabling controlled, lysosomal payload release. It is optimized for research workflows requiring high specificity in targeted drug delivery and is unsuitable for aqueous, diagnostic, or clinical applications.
8029 records 12/536 page Previous Next First page 上5页 1112131415 下5页 Last page